Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ovid Therapeutics Inc.OVID · Entity 5411 | SVP, Global Regulatory Affairs | December 17, 2020 | December 21, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ovid Therapeutics Inc.
Report date December 17, 2020 · Filed December 21, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.82 · Expires 2030-12-16 | Direct | 100,000 |
Reported balance
After 2020-12-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-12-17 · Grant · Acquired 100,000 · Balance 100,000 F1: 25% of the shares subject to the Stock Option will vest and become exercisable on December 17, 2021 and the remaining shares will vest in 36 equal monthly installments thereafter subject to the Reporting Person's continued services through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to the Stock Option will vest and become exercisable on December 17, 2021 and the remaining shares will vest in 36 equal monthly installments thereafter subject to the Reporting Person's continued services through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 17, 2020 Filed Dec 21, 2020 16:38 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $2.82 | $0.00 |
DisclosureSEC source: 0001209191-20-064649 · doc4.xml · derivative · entry 1 Haasner Dirk · CIK 0001704660 · SVP, Global Regulatory Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-12-16 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on December 17, 2021 and the remaining shares will vest in 36 equal monthly installments thereafter subject to the Reporting Person's continued services through such date. Read SEC document |
| October 11, 2020 Filed Oct 13, 2020 16:41 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | GrantStock option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $5.65 | $0.00 |
DisclosureSEC source: 0001209191-20-054645 · doc4.xml · derivative · entry 1 Haasner Dirk · CIK 0001704660 · SVP, Global Regulatory Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-10-10 F1 · derivative.exercise_date: 50% of the shares subject to the Stock Option will vest and become exercisable on October 11, 2021 and the remaining shares will vest in 12 equal installments thereafter, subject to the Reporting Person's continued service through each such date. Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 16:21 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $4.42 | $0.00 |
DisclosureSEC source: 0001209191-19-061548 · doc4.xml · derivative · entry 1 Haasner Dirk · CIK 0001704660 · SVP, Global Regulatory Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2029-12-17 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on December 18, 2020 and the remaining shares will vest in 36 equal monthly installments thereafter subject to the Reporting Person's continued services through such date. Read SEC document |
| February 24, 2019 Filed Feb 26, 2019 21:43 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | GrantEmployee Stock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $1.89 | $0.00 |
DisclosureSEC source: 0001209191-19-013906 · doc4.xml · derivative · entry 1 Haasner Dirk · CIK 0001704660 · SVP, Global Regulatory Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2029-02-23 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on February 24, 2020 and the remaining shares will vest in 36 equal monthly installments thereafter subject to the Reporting Person's continued services through such date. Read SEC document |
| August 27, 2018 Filed Aug 29, 2018 18:24 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | GrantEmployee Stock Option (right to buy) · Derivative | 22,500 | $0.00 Strike: $6.40 | $0.00 |
DisclosureSEC source: 0001209191-18-048858 · doc4.xml · derivative · entry 1 Haasner Dirk · CIK 0001704660 · SVP, Global Regulatory Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2028-08-27 F1 · derivative.exercise_date: The option, representing a right to purchase a total of 22,500 shares becomes exercisable in two equal annual installments beginning on August 27, 2019, subject to the Reporting Person's continued service through each such date. Read SEC document |
| January 19, 2018 Filed Jan 23, 2018 16:40 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | GrantEmployee Stock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $9.18 | $0.00 |
DisclosureSEC source: 0001209191-18-004909 · doc4.xml · derivative · entry 1 Haasner Dirk · CIK 0001704660 · SVP, Global Regulatory Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2028-01-18 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on January 19, 2019 and the remaining shares will vest in 36 equal monthly installments thereafter subject to the Reporting Person's continued service through each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.